Can we improve the clinical risk score?
Ki-67 overexpression was a positive predictor of survival. Only high CRS remained an independent negative prognostic predictor.
Our study identified OX40 as a key molecule and biomarker for rapid progression of HAM/TSP. Furthermore, blocking OX40 may have potential in therapeutic intervention for HAM/TSP.